COVID-19 breakthrough infections in rheumatic diseases patients after vaccination

• Main Authors: Abeer N. Alshukairi (Author), Awad Al-Omari (Author), Abdurahman Albeity (Author), Thamir A. Alandijany (Author), Ahmed M. Hassan (Author), Sherif A. El-Kafrawy (Author), Ashraf Dada (Author), Mohammad K. Al Hroub (Author), Aiman El-Saed (Author), Lina S. Bissar (Author), Radwan M. Daghmush (Author), Saeed M.G. Al-Ghamdi (Author), Stanley Perlman (Author), Esam I. Azhar (Author), Hussein Halabi (Author)
• Format: Book
• Published: Elsevier, 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Rheumatic diseases patients receiving Rituximab had severe COVID-19 disease. Although they had impaired humoral immune responses following COVID-19 vaccine, they had preserved cellular immune responses. Waning of COVID-19 antibody responses was observed within six months post vaccination...